RICT 2017
Conferences > Upcoming events > RICT 2017
Wednesday July 5, 2017
08:00Registration & Welcome Coffee
09:00RICT 2017 Opening
09:30Session 1: Paul Ehrlich Award Lecture Sponsored by Janssen Research & Development
09:30Paul Ehrlich Award Lecture
Sponsored by Janssen Research & Development
Prof. Ben DAVIS
(OXFORD UNIVERSITY, Oxford, United Kingdom)
10:30Coffee break & Exhibition
Session 2: Peptides & sugars in drug discovery
11:00Peptide Drugs to Target GPCR- State of the Art and Innovative Application
Prof. Annette BECK-SICKINGER
(LEIPZIG UNIVERSITY, Leipzig, Germany)
11:45Lunch break & Exhibition
13:00Poster Session 1 & Exhibition
Session 3: Recent advances in immuno-oncology
14:30Small Molecule Approaches in Immune-Oncology
Dr Ronan O'HAGAN
(MERCK, SHARP & DOHME, Boston, United States)
15:15Title of talk to be confirmed
Dr Nicolas MEYER
(ONCOPOLE TOULOUSE, Toulouse, France)
16:00Novel Small Molecule MerTK Inhibitors and their Biological Uses
Prof. Xiaodong WANG
(UNIVERSITY OF NORTH CAROLINA, Chapel Hill, United States)
16:45Discovery of PF-06840003, a Novel IDO Inhibitor for Cancer Immunotherapy
Dr Stefano CROSIGNANI
(ITEOS THERAPEUTICS SA, Gosselies, Belgium)
17:30Welcome & Networking Reception
19:00End of Day 1
Thursday July 6, 2017
Session 4: Inspired by nature
08:30De Novo Drug Design — Inspiration from Nature
Prof. Gisbert SCHNEIDER
(ETH ZÜRICH, Zürich, Switzerland)
Session 5: Inspired by natureSession 6: Advances in kinase inhibitors discovery
09:15New Modalities inspired by nature: from Genetic Encoding of Cyclic Peptides to Hybrid Macrocycles
Dr Eric VALEUR
(ASTRAZENECA, Västra Frölunda, Sweden)
09:45Post-functionalization of RNAs for Specific Conjugations with Peptides and Proteins
Prof. Mélanie ETHEVE-QUELQUEJEU
(UNIVERSITÉ PARIS DESCARTES, Paris, France)
09:15Discovery of Mnk1/2 Kinases Inhibitors for the Treatment of Leukaemia
Dr Kassoum NACRO
(EXPERIMENTAL THERAPEUTICS CENTER, Singapore, Singapore)
09:45Discovery of CDK8/CDK19 Kinase Modulators and Evaluation of their Therapeutic Potential
Dr Aurelie MALLINGER
(INSTITUTE OF CANCER RESEARCH, Sutton, London, United Kingdom)
10:15Coffee break & Exhibition
Session 5: Accessing novel chemical spaceSession 7: Structure based design
10:45Title of talk to be confirmed
Prof. Alexander DÖMLING
(UNIVERSITY OF GRONINGEN, RUG, Groningen, The Netherlands)
11:30Chemoselective and Biocompatible Reactions, New Tools for Heterocyclic Chemistry and Chemical Biology
Dr Frédéric TARAN
(CEA/SACLAY, Gif-sur-Yvette, France)
10:45First-in-class Extracellular Modulators of Receptor Tyrosine Kinases: from Theory to Practice
Prof. Didier ROGNAN
(UNIVERSITY OF STRASBOURG, Illkirch, France)
11:30Structure-based Drug Design (SBDD) in Medicinal Chemistry-enabled Drug Discovery
Dr Hong SHEN
(F. HOFFMANN-LA ROCHE, Shanghai, China)
12:15Lunch break & Exhibition
13:00Poster Session 2 & Exhibition
Session 8: New tools for therapeutic innovationSession 9: Advances in proteases inhibitor discovery
14:30Impact of Zinc in Therapeutic Approaches to Fight Alzheimer’s Disease
Dr Christelle HUREAU
(LABORATOIRE DE CHIMIE DE COORDINATION UPR 8241, Toulouse, France)
15:00Nanometric micelles for in vivo imaging and drug delivery
Dr Eric DORIS
(CEA, Gif-sur-Yvette, France)
14:30Discovery of Novel TACE Inhibitors for Topical Treatment of Psoriasis
Dr Gilles OUVRY
(GALDERMA R&D, SOPHIA ANTIPOLIS, France)
15:00Mining from NP-Like Fragments in 3D: Discovery of a Potent Caspase-1 Inhibitor
Dr Vincent RODESCHINI
(EDELRIS, LYON, France)
Session 10: Rare diseasesSession 11: Neglected diseases
15:30Partnering Early to Better Serve Patients Suffering from Rare and Devastating Diseases
Dr Jean-Philippe ANNEREAU
(ALEXION, Paris, France)
15:30Allosteric Inhibitors of Dengue and Zika Virus NS3/NS2B Proteases
Prof. Tanja SCHIRMEISTER
(UNIVERSITY OF MAINZ, Mainz, Germany)
16:15Coffee break & Exhibition
Session 12: Synthetic BiologySession 13: Tackling PPIs
16:45Xeno Nucleic Acids (XNA) in vivo : A New Medicinal Chemistry Approach?
Prof. Piet HERDEWIJN
(KU LEUVEN, Leuven, Belgium)
17:30Bioactive Ribosomal and Non-Ribosomal Peptides from Nature - Structures, Biosynthesis and Engineering Options
Prof. Roderich D. SÜSSMUTH
(TECHNICAL UNIVERSITY BERLIN, Berlin, Germany)
16:45Monitoring the Antagonist-Protein and Protein-Protein Interactions with NMR and X-ray: Inhibitors of the p53-Mdm2 and Immune Checkpoint PD-1/PD-L1 Interactions
Prof. Tad HOLAK
(MAX PLANCK INSTITUTE OF BIOCHEMISTRY, Martinsried, Germany)
17:30Engineering Alphabodies to Generate Potent Druggable Inhibitors of Intracellular Protein-Protein Interactions
Dr Ignace LASTERS
(COMPLIX, Zwijnaarde, Belgium)
18:15End of Day 2
18:30Cocktail at the City Hall
20:00Gala Dinner
Friday July 7, 2017
Session 14: Advances in kinase inhibitors discovery & development
08:30Development of Dual IGF1R/INSR Inhibitors a Case Study
Dr Heather TYE
(EVOTEC (UK) LTD, Abingdon, United Kingdom)
09:15Identifying High Quality, Potent and Selective Inhibitors of ATM Kinase for Oncology Therapies: Discovery of AZD0156
Dr Bernard BARLAAM
(ASTRAZENECA, Macclesfield, United Kingdom)
10:00Coffee break & Exhibition
10:30Raising the Gold Standard: Design & Development of Highly Selective JAK3 Probes (Janus Kinase 3)
Prof. Stefan LAUFER
(UNIVERSITY TÜBINGEN, Tübingen, Germany)
11:15Discovery of Leniolisib, a Novel and Selective PI3Kδ Inhibitor for Autoimmune and Inflammatory Diseases
Dr Nicolas SOLDERMANN
(NOVARTIS, Basel, Switzerland)
12:00Pierre Fabre Award lecture
13:00Closing remarks, prizes
13:30End of symposium
15:00Optional visit of the Airbus Facilities

Copyright 2017 LD Organisation  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 10 454777  |   |  VAT: BE 0464819842
Developed and powered by Antalys